DCIS: Margins and the USC/VNPI

Similar documents
What are Adequate Margins of Resection for Breast-Conserving Therapy?

SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer

BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO

BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO

ONCOPLASTIC BREAST SURGERY AT HOAG WE CAN SAVE YOUR BREASTS

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

What is an Adequate Lumpectomy Margin in 2018?

Spotlights on the surgery role at San Antonio

Ductal Carcinoma-in-Situ: New Concepts and Controversies

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

The Case FOR Oncoplastic Surgery in Small Breasts. Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA

Personalized Treatment of DCIS

Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006

SENTINEL LYMPH NODE BIOPSY FOR PATIENTS WITH EARLY-STAGE BREAST CANCER

Ahmad Elahi*, Gholamreza Toogeh,Habibollah Mahmoodzadeh, Behnaz Jahanbin, Farhad Shahi,

Clinical Scholars Program Getting to Know Our Scholars 2011

Radiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Resection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland

Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016

Speaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Evolution of Breast Surgery

2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Prophylactic Mastectomy State of the Art

Abstract 80 DCIS Treated With Excision Alone Using the National Comprehensive Cancer Network (NCCN) Guidelines

Key Ouestions. to ask your medical oncology team after being diagnosed with breast cancer

Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

Conservative Surgery and Radiation Stage I and II Breast Cancer

Angela Gilliam, MD University of Colorado Surgical Grand Rounds November 3, 2008

Approved Date: 6/2011, 8/2014 Approval By: Allina Health Breast Program Committee. Departments, Divisions, Operational Areas

2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features

San Antonio Breast Cancer Symposium Highlights A Surgeon s Perspective

Advances in Localized Breast Cancer

The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer

Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)

State of the Art in 2000 State of the Art today Gazing forward

Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin

Disclosure. Objectives 03/19/2019. Current Issues in Management of DCIS Radiation Oncology Considerations

Corporate Medical Policy

Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery

259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

Radiation Therapy for the Oncologist in Breast Cancer

PRACTICE GUIDELINE FOR BREAST CONSERVATION THERAPY IN THE MANAGEMENT OF INVASIVE BREAST CARCINOMA

The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer

Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy

Protocol of Radiotherapy for Breast Cancer

Sentinel Lymph Node Biopsy for Breast Cancer

Breast Surgery: Yesterday, Today and Tomorrow

4/13/2010. Silverman, Buchanan Breast, 2003

How can we Personalize RT as part of Breast-Conserving Therapy?

Early and locally advanced breast cancer: diagnosis and management

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

A DEEPER DIVE INTO DUCTAL CARCINOMA IN SITU: CLINICAL AND PATHOLOGIC CONSIDERATIONS IN 2015

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

Bruno CUTULI Policlinico Courlancy REIMS. WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ

IORT What We ve Learned So Far

Results of the ACOSOG Z0011 Trial

Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective

Principles of breast radiation therapy

Cryoablation in the Management of Early Stage Breast Cancer

Relevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:

Surgical Issues in Neoadjuvant Chemotherapy

New Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011

Consensus Guideline on Breast Cancer Lumpectomy Margins

GOALS AND OBJECTIVES BREAST PATHOLOGY

The Role of Sentinel Lymph Node Biopsy and Axillary Dissection

Are too many mastectomies being done in the U.S.? Patrick Ivan Borgen, MD Surgeon-in-Chief Maimonides Medical Center Brooklyn, New York

Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar

Surgery for Breast Cancer

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital

Advances in Breast Cancer Diagnosis and Treatment. Heidi Memmel, MD FACS Surgical Director of Caldwell Breast Center September 26, 2015

Surgical Margins in Breast Cancer: Finally Defined?

Early and locally advanced breast cancer: diagnosis and management

Standards for Diagnosis and Management of Ductal Carcinoma in Situ (DCIS) of the Breast

Clinical Outcomes of Ductal Carcinoma In Situ of the Breast Treated with Partial Mastectomy without Adjuvant Radiotherapy

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction

Is Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group

Slide 1. Slide 2. Slide 3 History of Nurse Navigator

03/14/2019. Postmastectomy radiotherapy; the meta-analyses, and the paradigm change to altered fractionation Mark Trombetta M.D.

Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience

Use of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Ductal Carcinoma In Situ of the Breast: Controversial Issues

Disclosures. Premalignant Lesions of the Breast: What Clinicians Want and Why. NY Times: Prone to Error: Earliest Steps to Find Cancer.

Breast Cancer: Current Approaches to Diagnosis and Treatment

Breast Cancer. Saima Saeed MD

Is Lobular Carcinoma In Situ as a Component of Breast Carcinoma a Risk Factor for Local Failure after Breast-Conserving Therapy?

Types of Breast Cancer

Transcription:

DCIS: Margins and the USC/VNPI Van Nuys USC Hoag Melvin J. Silverstein, M.D Gross Endowed Chair in Oncoplastic Surgery Director, Hoag Breast Program Newport Beach, CA Clinical Professor of Surgery Keck School of Medicine University of Southern California

No Ink on Tumor is Adequate Clinical Investigation: Breast Cancer Society of Surgical OncologyeAmerican Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer Invasive Cancer Treated with Radiation Therapy Meena S. Moran, MD,* Stuart J. Schnitt, MD, y Armando E. Giuliano, MD, z Jay R. Harris, MD, x Seema A. Khan, MD, k Janet Horton, MD, { Suzanne Klimberg, MD, # Mariana Chavez-MacGregor, MD,** Gary Freedman, MD, yy Nehmat Houssami, MD, PhD, zz Peggy L. Johnson, xx and Monica Morrow, MD kk +/- Chemo/Hormonal *Department of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut; y Department of Pathology, Harvard Medical School, Boston, Massachusetts; z Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California; x Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts; k Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois; { Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina; # Department of Surgery, University of Arkansas for Medical Sciences, Fayetteville, Arkansas; **Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; yy Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; zz School of Public Health, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; xx Advocate in Science, Susan G. Komen, Wichita, Kansas; and kk Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York Received Oct 3, 23. Accepted for publication Nov 6, 23. International Journal of Radiation Oncology biology physics www.redjournal.org Nothing to do with Pure DCIS Particularly when Treated with Excision Alone

Update Data through 23 673 DCIS Patients 86 Months Median Follow Up

Local Recurrence-Free Survival.2.8.6.4.2 563 Mastectomy 42 Radiation Therapy All p <. 689 Excision Only 2.3% 8% 29% 2 3 4 5 6 7 8 9 2 Years 673 DCIS

Breast Cancer Specific Survival.2.8.6 No Difference REGARDLESS of Treatment.8%.4.2 563 Mastectomy 42 Radiation Therapy 689 Excision Only p = NS 2 3 4 5 6 7 8 9 2 Years 673 DCIS

Overall Survival.2 8%.8.6 No Difference REGARDLESS of Treatment.4.2 563 Mastectomy 42 Radiation Therapy 689 Excision Only p = NS 2 3 4 5 6 Years 7 8 9 2 673 DCIS

987 to the Present Published > Papers Fighting Over-Diagnosis and Over-Treatment DCIS

NCCN Practice Guidelines 28 DCIS Lumpectomy without lymph node surgery + whole breast radiation therapy DCIS or Total mastectomy with or without sentinel node biopsy +/- reconstruction or Lumpectomy e without lymph node surgery without radiation therapy

Margins

33 Original NEJM Patients Margins mm Median Follow-up 5. Years 2% 3% p = NS 4 Radiation Therapy 93 Excision Only

Margins are like money, more is better, when treating DCIS with excision alone Keynote Address American Society of Breast Surgeons Annual Meeting La Jolla, California May 4, 2

Because of that Statement and the NEJM Paper, I Incorrectly Became the Leading Proponent for mm Margins For All Breast Cancers: DCIS and Invasive Word Spread I Would Accept Nothing Less Than mm I Re-Excised or Converted to Mastectomy for < mm

Because of that Statement and the NEJM Paper, I Incorrectly Became the Leading O Proponent for mm Margins For All Breast Cancers: DCIS and Invasive Word Spread I Would Accept Nothing Less Than mm I Re-Excised or Converted to Mastectomy for < mm

My Postion Has Always Been. Irradiate All Conservatively Treated Patients with Invasive Breast Cancer with Negative Margins 2. I Do Not Irradiate SELECTED Patients with DCIS 3. For Those Not Irradiated, I Prefer a Wider Margin

.2 Local Recurrence By Margin Width 697 DCIS Treated by Excision Alone Probability Recurrence.8.6.4.2 -.2-2 Local Recurrence Decreases as Margin Width Increases p =. 2 6 4 8 Margin Width (mm)

UPDATE

Original NEJM Patients by Rx Margins mm Median Follow-up 5. Years 2% 3% p = NS 4 Radiation Therapy 93 Excision Only

.2 Original 33 NEJM Patients by Rx Margins mm Median Follow-up.9 Years.8 2.3% 8.6%.6.4.2 4 Radiation Therapy 93 Excision Only p = NS 2 3 4 5 6 Years 7 8 9 2

.2 42 BCT DCIS Patients All Margins mm.8 4% 6%.6.4.2 6 Radiation Therapy 36 Excision Only p =.2 2 3 4 5 6 Years 7 8 9 2

.2 42 BCT DCIS Patients All Margins mm.8 4% 6%.6.4 Gold Standard for Excision + RT NSABP B7 = 6% @ 2-Yrs.2 6 Radiation Therapy 36 Excision Only p =.2 2 3 4 5 6 Years 7 8 9 2

.2 42 BCT DCIS Patients All Margins mm.8 4% 6%.6.4 Gold Standard for Excision + RT NSABP B7 = 6% @ 2-Yrs Excision Alone = 32%.2 6 Radiation Therapy 36 Excision Only p =.2 2 3 4 5 6 Years 7 8 9 2

.2 42 BCT DCIS Patients All Margins mm.8.6.4 Gold Standard for Excision + RT NSABP B7 = 6% @ 2-Yrs Excision Alone = 32% 4% 6% 32%.2 6 Radiation Therapy 36 Excision Only p =.2 2 3 4 5 6 Years 7 8 9 2

Margins By Themselves Are OK But if 6% IBTR Too Much Add Tamoxifen Use USC/VNPI

CANCER 996 Margin Width, Size, Grade, Necrosis

Added Age AJS 22

USC / Van Nuys Prognostic Index Score 2 3 Size 5 mm 6-4 > 4 Margin mm - 9 < VN Class Grade /2 without Necrosis Grade /2 with Necrosis Grade 3 Age > 6 4-6 < 4

Looked at Every Individual USC/ VNPI Score (4, 5, 6, 7, 8, 9,,, 2) by Various Margins Widths (, 2, 3, 5, mm) With and Without RT

Developed Treatment Guidelines for Maximum Allowable Recurrence Limits %, 5%, 2% 25%, 3%

.2 Local Recurrence-Free Survival 375 USC/VNPI = 4, 5 or 6 by TREATMENT.8 3.6% 7.2%.6.4.2 84 Radiation Therapy 29 Excision Only p =.39 2 3 4 5 6 Years 7 8 9 2

Local Recurrence-Free Survival 262 USC/VNPI = 7 by TREATMENT.2.8.6.4 Done Radiation Therapy p =.23 4% 29%.2 6 Excision Only 2 3 4 5 6 7 8 9 2 Years

Local Recurrence-Free Survival 9 USC/VNPI = 7, Margins 3 mm.2.8 6%.6.4 9 Excision Alone.2 2 3 4 5 6 7 8 9 2 Years

Local Recurrence-Free Survival 4 USC/VNPI =, or 2.2.8 p =.2.6.4 53%.2 58 Radiation Therapy 56 Excision Only 92% 2 3 4 5 6 7 8 9 2 Years

24 Treatment Guidelines Based on Less than 2% Local Recurrence as Acceptable USC / VNPI Treatment 2-Yr Recur 4, 5 or 6 Excision Alone 8% 7, Margins 3 mm Excision Alone 6% 7, Margins < 3 mm Radiation 4% 8, Margins 3 mm Radiation 4% 8, Margins < 3 mm Mastectomy % 9, Margins 5 mm Radiation 7% 9, Margins < 5 mm Mastectomy %, or 2 Mastectomy 7%

.2 Local Recurrence-Free Survival USC/VNPI 4-9 vs -2 563 Treated by Mastectomy.8.6 p =.29.5% 6.6%.4.2 289 - USC/VNPI = 4-9 (2 Recurrences) 274 - USC/VNPI = -2 (8 Recurrences) 2 3 4 5 6 Years 7 8 9 2

CONCLUSIONS. Excision Alone is Acceptable Treatment for Selected DCIS Patients per NCCN Guidelines 2. 35% of DCIS Patients currently treated with Excision Alone 3. mm Margins Work 4. Best Selection Criteria are Based on Size, Grade, Necrosis, Margin Width and Age (USC/VNPI)

Thank You